AstraZeneca licenses rights to Synairgen asthma drug

LONDON, June 12 (Reuters) - AstraZeneca has struck a deal worth up to $232 million in milestone payments to license in rights to a drug from Synairgen for viral-induced exacerbation in asthma.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.